Actively Recruiting
Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation
Led by Central Hospital, Nancy, France · Updated on 2023-06-05
200
Participants Needed
1
Research Sites
356 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COV Preserved study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with preserved left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.
CONDITIONS
Official Title
Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic acute heart failure with preserved ejection fraction admitted for scheduled day hospitalization or consultation
- Preserved left ventricular ejection fraction (≥50%)
- Age 18 years or older
- Patients informed about the study and who have signed informed consent
- Patients affiliated with or beneficiaries of a social security scheme
You will not qualify if you...
- Comorbidity with life expectancy 3 months or less
- Dialysis patients or those with glomerular filtration rate below 15 ml/min/m2 at inclusion
- History of lobectomy or pneumonectomy lung surgery
- Severe lung or pleural disease preventing reliable lung ultrasound (e.g., emphysema, chronic pleurisy, pulmonary fibrosis)
- Pregnant, parturient, or nursing women
- Adults under legal protection measures (guardianship, curatorship, safeguard of justice)
- Adults unable to give consent
- Persons deprived of liberty by judicial or administrative decision
- Persons under psychiatric care according to specific public health codes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU de Nancy
Vandœuvre-lès-Nancy, France, 54500
Actively Recruiting
Research Team
N
Nicolas GIRERD, MD, PhD
CONTACT
S
Sanae BOUALI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here